Bucking trends.
Backed by experience. 

For more than a decade, Dr. Travis Stiles has exclusively studied the mechanisms underlying regenerative failure in the CNS. His work led to the discovery of a novel therapeutic target for the promotion of neuronal tissue regeneration after CNS damage and disease. To best translate his work into viable therapies, Dr. Stiles co-founded Novoron Bioscience early in 2014.

Dr. Stiles earned a PhD in Biomedical Science from the University of California, San Diego (UCSD), an MA in Exercise Physiology from the University of the Pacific, and a BA in Exercise Science from Willamette University. He has been recognized as a top innovator by groups such as J&J and Biocom and has been awarded over $3 million in federal grants. In addition, Dr. Stiles has served on multiple scientific review boards for the National Institute of Health and recently completed a four-year Federal Advisory Committee appointment to the Scientific Merit Review Board subcommittee for Regenerative Medicine in the Department of Veterans Affairs.

Shawn Gahr is a Co-founder and Board Member of Novoron Bioscience, where he has played a key role in securing funding through multiple rounds. With over a decade of experience in financial planning and analysis, Shawn has worked with Fortune 500 companies across industries like healthcare, financial services, IT, government, and automotive. He has also contributed to business development, project management, and strategic efforts for successful startups. Shawn holds a BS in Economics from Willamette University and a Master’s degree in International Economics from University of California, San Diego (UCSD), bringing a diverse background to his work in biotechnology and finance.

Mr. Drummond has more than 15 years experience working in the medical research sector. Initially, he worked as a laboratory scientist at The University of Melbourne, investigating the role of post-translational modifications to myelin antigens as a potential cause of multiple sclerosis.

In 2012, Mr. Drummond co-founded MStranslate - a science communication initiative designed to provide accurate and easy to understand updates on the latest in multiple sclerosis research to the MS community. His work in this area has been recognised worldwide, also leading him to be selected as the host of the official European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) podcast series.

After completing her PhD at Monash University, Dr. Bye has spent more than 20 years contributing to neuroscience research. Her post-doctoral appointments, undertaken at Monash University, The Alfred Hospital and The University of Melbourne, involved investigating the mechanisms of pathology and regenerative pathways in traumatic brain injury.

Dr. Bye has authored more than 20 peer-reviewed publications on her research and 4 book chapters. Her excellent work was recognised by being awarded an early-career research fellowship from the Victorian Neurotrauma Initiative.

Dr Dave Gell is a protein scientist with close to three decades of research experience at the bench. Hailing from Liverpool and Yorkshire in the UK, he completed his PhD in protein biochemistry at the University of Cambridge, then spent ten years training in structural biology (protein NMR and x-ray crystallography) as a postdoctoral fellow at the University of Sydney.

Dave then set up a research group at the University of Tasmania, where he now holds an adjunct position. His research has been supported by fellowships and research grants from the Wellcome Trust (UK), the ARC and the NHMRC. He has enjoyed collaborations with groups in Australia, Europe and the US to make meaningful contributions in many areas of biology, including neuroscience, cancer, red blood cell production and host-microbe interactions. This work has received over 3400 citations (Web of Science) and includes publications in high-profile journals such as Cell, Nature and the Journal of Clinical Investigation.